Aclaris Therapeutics, Inc. (ACRS) vs Monopar Therapeutics Inc. (MNPR)
A side-by-side comparison of Aclaris Therapeutics, Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRS
Aclaris Therapeutics, Inc.
$4.04HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
MNPR
Monopar Therapeutics Inc.
$78.23HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
Total return — ACRS vs MNPR
growth of $100 · dividends reinvested · last 7yACRS +135.9% (+13.0%/yr)MNPR -40.9% (-7.2%/yr)ACRS compounded faster over this window
ACRS MNPR
ACRS vs MNPR: by the numbers
- •ACRS is the larger company ($564M vs $524M market cap).
- •Both run net losses; MNPR's is the smaller (0.00% vs -921.50% net margin).
Metrics side by side
Valuation
| Metric | ACRS | MNPR |
|---|---|---|
| P/S ratio | 68.57 | N/A |
| P/B ratio | 4.52 | 4.00 |
Profitability
| Metric | ACRS | MNPR |
|---|---|---|
| Gross margin | 73.28% | 0.00% |
| Operating margin | -975.91% | 0.00% |
| Net margin | -921.50% | 0.00% |
| ROE | -60.79% | -13.64% |
| ROIC | -56.99% | -16.89% |
Growth (annualized)
| Metric | ACRS | MNPR |
|---|---|---|
| Revenue CAGR (5Y) | 4.39% | N/A |
| Total return CAGR (5Y) | -24.23% | 27.38% |
Frequently asked
- How have ACRS and MNPR total returns compared?
- Over the past 5 years, ACRS delivered -24.23% and MNPR delivered 27.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.